Share on StockTwits

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) released its earnings data on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.01, American Banking reports.

CPRX has been the subject of a number of recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Catalyst Pharmaceutical Partners in a research note on Monday, April 14th. They set an “overweight” rating and a $4.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Catalyst Pharmaceutical Partners in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Catalyst Pharmaceutical Partners currently has a consensus rating of “Buy” and a consensus price target of $3.41.

Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.77 on Friday. Catalyst Pharmaceutical Partners has a 52 week low of $0.80 and a 52 week high of $3.65. The stock’s 50-day moving average is $2.05 and its 200-day moving average is $1.97. The company’s market cap is $95.8 million.

Catalyst Pharmaceutical Partners, Inc is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.